Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01432600 · FLOW

Participant flow

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide · Source last updated 2017-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide.
    id
    FG000
    title
    A: Dose Escalation of Cyclophosphamide
  2. description
    Phase II: Pomalidomide and high dose dexamethasone. Arm D participants may be referenced separately in some Outcome Measures.
    id
    FG001
    title
    B: Pomalidomide and Dexamethasone
  3. description
    Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.
    id
    FG002
    title
    C: Pomalidomide, Dexamethasone, Cyclophosphamide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      type
      Rapid PD, allocated intv. not rec'd
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        36
      3. group Id
        FG002
        num Subjects
        34
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        35
      3. group Id
        FG002
        num Subjects
        33
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Between December 2011 and March 2014, participants were enrolled at: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY.
Complete source fields
groups
  1. description
    Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide.
    id
    FG000
    title
    A: Dose Escalation of Cyclophosphamide
  2. description
    Phase II: Pomalidomide and high dose dexamethasone. Arm D participants may be referenced separately in some Outcome Measures.
    id
    FG001
    title
    B: Pomalidomide and Dexamethasone
  3. description
    Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.
    id
    FG002
    title
    C: Pomalidomide, Dexamethasone, Cyclophosphamide
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      type
      Rapid PD, allocated intv. not rec'd
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        36
      3. group Id
        FG002
        num Subjects
        34
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        10
      2. group Id
        FG001
        num Subjects
        35
      3. group Id
        FG002
        num Subjects
        33
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Between December 2011 and March 2014, participants were enrolled at: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice